论文部分内容阅读
目的研究hnRNP L蛋白在前列腺癌中的表达及临床意义。方法收集我院2011年1月至2013年5月期间行前列腺癌根治术后标本60例,良性前列腺增生(BPH)组织标本40例。采用Western blot及免疫组化法检测hnRNP L蛋白在前列腺癌及良性前列腺增生组织中的表达,并分析其表达与临床病理参数之间的关系。结果 Western blot结果显示hnRNP L蛋白在前列腺癌组织中的表达明显高于良性前列腺增生组织(P<0.05)。免疫组化结果表明hnRNP L蛋白阳性表达于细胞核,其在前列腺癌及前列腺增生组织中的阳性表达率分别为66.7%、17.5%,差异具有统计学意义(P<0.05)。此外,hnRNP L在前列腺癌组织中的表达与T分期、临床分期以及Gleason评分密切相关(P<0.05)。结论 hnRNP L高表达于前列腺癌组织,与前列腺癌的发生发展存在相关关系,有可能作为前列腺癌早期诊断标志物和治疗靶点。
Objective To study the expression of hnRNP L protein in prostate cancer and its clinical significance. Methods 60 cases of prostate cancer radical prostatectomy and 40 benign prostatic hyperplasia (BPH) tissue samples from January 2011 to May 2013 in our hospital were collected. The expression of hnRNP L protein in prostate cancer and benign prostatic hyperplasia tissues was detected by Western blot and immunohistochemistry. The relationship between the expression of hnRNP L protein and clinicopathological parameters was analyzed. Results The results of Western blot showed that the expression of hnRNP L protein in prostate cancer tissues was significantly higher than that in benign prostatic hyperplasia tissues (P <0.05). Immunohistochemical results showed that hnRNP L protein was positively expressed in the nucleus and its positive rates in prostate cancer and benign prostatic hyperplasia were 66.7% and 17.5%, respectively, with statistical significance (P <0.05). In addition, the expression of hnRNP L in prostate cancer was closely related to T stage, clinical stage and Gleason score (P <0.05). Conclusion The high expression of hnRNP L in prostate cancer tissue correlates with the occurrence and development of prostate cancer, which may serve as an early diagnostic marker and therapeutic target for prostate cancer.